Teva Pharmaceutical Industries Limited Sponsored ADR Stock

$16.69

2.51% yesterday

NYSE, Nov 25, 10:00 pm CET

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Teva Pharmaceutical Industries Limited Sponsored ADR Stock price

$16.69

+5.97 55.69% 5Y

NYSE, Closing price Mon, Nov 25 2024

-0.43 2.51%

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$18.91b
Enterprise Value	$35.18b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	12.84
EV/Sales (TTM) EV/Sales	2.09
P/S ratio (TTM) P/S ratio	1.12
P/B ratio (TTM) P/B ratio	3.12
Revenue growth (TTM) Revenue growth	9.85%
Revenue (TTM) Revenue	$16.81b
EBIT (operating result TTM) EBIT	$3.77b
Free Cash Flow (TTM) Free Cash Flow	$2.74b
Cash position	$3.32b
EPS (TTM) EPS	$-0.85
P/E forward	negative
P/S forward	1.15
EV/Sales forward	2.14
Short interest	1.61%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Teva Pharmaceutical Industries Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

??

12 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

10x Buy

83%

2x Hold

17%

More details on Analyst Estimates Including Price Targets

12 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

Buy

83%

Hold

17%

Analyst Estimates with Stock Price Targets

Financial data from Teva Pharmaceutical Industries Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	16,814 16,814	10% 10% 100%
- Direct Costs	8,412 8,412	2% 2% 50%
Gross Profit	8,402 8,402	19% 19% 50%
- Selling and Administrative Expenses	2,594 2,594	16% 16% 15%
- Research and Development Expense	978 978	4% 4% 6%
EBITDA	4,830 4,830	25% 25% 29%
- Depreciation and Amortization	1,056 1,056	11% 11% 6%
EBIT (Operating Income) EBIT	3,774 3,774	42% 42% 22%
Net Profit	-959 -959	57% 57% -6%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Teva Pharmaceutical Industries Limited Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

about 14 hours ago

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

TEL AVIV, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and Eric Hughes, Teva's Executive Vice President of Global R&D and Chief Medical Officer, will present at the 7th Annual Evercore ISI HealthCONx Conference on Thursday, December 5, 2024. The presentation will begin at 8:20 ...

Neutral

Seeking Alpha

●

7 days ago

Teva Pharmaceutical Industries Limited (TEVA) Jefferies London Healthcare Conference (Transcript)

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Jefferies London Healthcare Conference November 19, 2024 3:30 AM ET Company Participants Richard Francis - President & CEO Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo Good morning, everyone. Thanks for joining us.

Neutral

GlobeNewsWire

●

18 days ago

Teva to Present at the Jefferies London Healthcare Conference

TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024. The presentation will begin at 8:30 A.M. Greenwich Mean Time (3.30 A.M. Eastern Time).

More Teva Pharmaceutical Industries Limited Sponsored ADR News

Company Profile

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Head office	Israel
CEO	Richard Francis
Employees	37,226
Founded	1901
Website	www.tevapharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now